Results 61 to 70 of about 12,381 (205)

Thoracic radiotherapy may enhance the survival of patients with low‐risk advanced lung adenocarcinoma based on protein biomarkers

open access: yesPrecision Radiation Oncology, EarlyView.
The prognosis of LUAD was significantly influenced by many clinical and protein biomarkers. A risk model was developed to help identify advanced LUAD patients who would benefit from thoracic radiotherapy, and thoracic radiotherapy just significantly improved the survival of low‐risk patients but not that of high‐risk.
Chunliu Meng   +7 more
wiley   +1 more source

Early Diagnosis of Alzheimer's Disease by NIRF Spectroscopy\ud and Nuclear Medicine\ud [PDF]

open access: yes, 2011
Novel approaches to Early Diagnosis of Alzheimer's Disease by NIRF Spectroscopy and Nuclear Medicine are presented and related cognitive, as well as molecular and cellular, models are critically evaluated ...
Baianu, Prof.Dr. I.C.
core  

Trace Element Analysis in Human Neuroblastoma Cell Spheroids Supplemented With ZnCl2 by Micro‐XRF

open access: yesX-Ray Spectrometry, EarlyView.
ABSTRACT Neuroblastoma, the most common extracranial solid tumor of childhood, is responsible for ~10% of pediatric cancer deaths and has high potential for metastasis. Metals are extremely important in biological processes, and changes in their levels have been correlated with the development of cancerous growth.
J. E. P. Rosa   +10 more
wiley   +1 more source

Antibody conjugates in neuroblastoma: a step forward in precision medicine

open access: yesFrontiers in Oncology
Neuroblastoma (NB) is a pediatric cancer that often manifests in a high-risk form and is characterized by frequent relapses and resistance to conventional therapies.
Jihane Balla   +5 more
doaj   +1 more source

Hematopoietic stem cell transplantation in B- and T-cell lymphoma [PDF]

open access: yes, 2013
Huijgens, P.C. [Promotor]Mulder, C.J.J. [Promotor]Dongen, G.A.M.S.
Visser, O.
core   +2 more sources

Prognostic Impact of Treatment Modalities, Including Targeted Compartmental Radio‐Immunotherapy, in a Cohort of Neuroblastoma Patients With CNS Metastases at Relapse

open access: yesPediatric Blood &Cancer, Volume 73, Issue 4, April 2026.
ABSTRACT Introduction Neuroblastoma (NB) with central nervous system (CNS) metastases is rare at diagnosis, but occurs more often during relapse/progression. Patients with CNS metastases face a dismal prognosis, with no standardized curative treatment available.
Vicente Santa‐Maria Lopez   +13 more
wiley   +1 more source

Radioimmunoterapy: a promising therapeutic approach to treat ovarian carcinoma [PDF]

open access: yes, 2015
O cancro do ovário é a neoplasia ginecológica com maior índice de mortalidade entre a população do sexo feminino apesar dos consideráveis progressos verificados no seu tratamento.
Oliveira, Maria Cristina   +1 more
core   +2 more sources

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

open access: yesAmerican Journal of Hematology, Volume 101, Issue 4, Page 832-863, April 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) is the most common type of NHL in the Western Hemisphere. It comprises a heterogenous group of lymphomas, with different biology and clinical prognoses. R‐CHP remains the backbone of therapy, and frontline therapeutic options in fit patients are pola‐R‐CHP and R‐CHOP, whereas elderly or frail/unfit ...
Elise A. Chong   +2 more
wiley   +1 more source

Multifunctional Au@AgBiS2 Nanoparticles as High‐Efficiency Radiosensitizers to Induce Pyroptosis for Cancer Radioimmunotherapy

open access: yesAdvanced Science, 2023
Radiotherapy (RT), a widely used clinical treatment modality for cancer, uses high‐energy irradiation for reactive oxygen species (ROS) production and DNA damage.
Liang Xiao   +6 more
doaj   +1 more source

Improvement of Radioimmunotherapy Using Pretargeting [PDF]

open access: yes, 2013
During the past two decades, considerable research has been devoted to radionuclide therapy using radiolabeled monoclonal antibodies and receptor binding agents.
Caroline Bodet-Milin   +5 more
core   +1 more source

Home - About - Disclaimer - Privacy